|Bid||77.51 x 1100|
|Ask||77.44 x 1300|
|Day's Range||75.00 - 86.43|
|52 Week Range||20.10 - 300.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||127.50|
Although the majority of U.S.-based cannabis companies and many foreign ADRs trade over-the-counter, a few marijuana companies are traded on the NASDAQ. Some investors prefer stocks that are listed on the NASDAQ to other exchanges due to their increased liquidity and tighter spreads than the OTC markets.
HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Here are some of the best plays trading at or near their 52 week low, that look positioned to breakout in the near term. One that you should look at right ...
Ryan McQueeney and Maddy Johnson discuss earnings results from Netflix and the big U.S. banks. The hosts also remember the legacy of Jack Bogle and chat about several new cannabis industry deals.
HEXO Gets Approval to Be Listed on the NYSE AmericanHEXO On January 17, HEXO (HEXO) announced that it received approval to be listed on the NYSE (New York Stock Exchange) American. The stock will start trading under the ticker “HEXO” on January
Analysts' January Rating Updates for TLRY, CGC, and ACB(Continued from Prior Part)Canopy GrowthCanopy Growth (WEED) (CGC) has continued to deepen its roots in the United States with a recent announcement that could be a game changer for the company.
Analysts' January Rating Updates for TLRY, CGC, and ACB(Continued from Prior Part)Aurora Cannabis Aurora Cannabis (ACB) stock tanked nearly 8.2% after the market closed on January 16 due to the company’s announcement that it would raise ~$250
Given that diseases are becoming more difficult to treat, it would seem that we are in desperate need of major advancements in healthcare technology, and many of these steps forward have been made possible through the advent of legalized medical marijuana. Towards the tail-end of last year, Canadian Prime Minister Justin Trudeau and members of the Canadian government agreed to legalize recreational/medicinal cannabis usage, resulting in a rush of energy for Canada's cannabis industry. With the global medical marijuana market predicted to reach $55.0 billion by 2024, according to a new research study published by Global Market Insights, Inc, it stands to reason that companies with the ability to combine the complex medical applications of cannabis with integrative healthcare frameworks could create potential opportunities from entering the nascent marijuana industry.
It's gimmicky to be sure. Yet, it's also brilliant. On Wednesday, New Age Beverages (NASDAQ:NBEV) unveiled a new line of cannabis-infused drinks that will utilize the name and fame of late reggae star Bob Marley to launch Marley+CBD. The agreement pairs a niche maker of teas and flavored waters with a well-known entertainer who is widely remembered as a fan of marijuana. The news wasn't terribly surprising, given the response from NBEV stock owners. Shares were up slightly in front of the announcement that a conference call had been scheduled to discuss then-unknown news, and New Age Beverages stock actually fell once investors learned of the new product and label. This is a development, however, that may need a slow burn to fully demonstrate the potential of a Marley-branded, cannabis-based drink. NBEV could be a good buy for investors interested in pot stocks, but hesitant about a pure-marijuana play. InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### Sign of the Times In some regards this was inevitable. * 10 Growth Stocks With the Future Written All Over Them Last year was a huge year for cannabis, with sweeping legalization in Canada -- though cannabis drinks are not yet legal in Canada -- and legalization progress in the United States. Partnerships began taking shape in earnest, with some major names showing interest in the business without even knowing exactly how they could or should plug into the legalized marijuana market. Constellation Brands (NYSE:STZ) was arguably the first big name to take the plunge, making a modest investment in Canada's marijuana producer Canopy Growth (NYSE:CGC) early last year and then upping that investment to a $4 billion, 38% stake in August. Anheuser Busch (NYSE:BUD) forged its tie-up with Tilray (NASDAQ:TLRY) in December to explore the development of THC and CBD-infused beverages. Even PepsiCo (NASDAQ:PEP) has acknowledged it's mulling the possibility. ### Marley+CBD Enters a Crowded Market The first product to launch under the Marley+CBD label will be relaxation drink Mellow Mood, soon to be available Colorado, Oregon, Washington, and Michigan. The 15.5 ounce can will contain 25 milligrams of cannabidiol, which does not cause a 'high' like THC (tetrahydrocannabinol) does, but still offers a variety of physical benefits The company implied that more Marley+CBD beverages may be on the way. Investors shouldn't think, however, that New Age Beverages has beaten bigger, better-funded players to the market. The cannabis-based beverage market is already fairly crowded. Tinley, Level+, Dixie, Stillwater, Mood33, Mad Hatter and Brewbudz are just some of the brands of CBD and THC-infused drinks already available, where such beverages are legal. In fact, New Age itself already launched a cannabis-infused drink back in October. The existing and future competitors within the CBD beverage market are a reflection of growing demand. Still, the Marley name is a powerful one, as is the New Age Beverages moniker. ### Modest Market Size In 2017, it was estimated that the legal marijuana market was worth $9 billion.That was before Canada legalized it, and with only a handful of U.S. states on board. By 2022, as pot is legalized in more places, the market could grow to $23 billion. Of those figures, the vast majority of the money has been and will be spent on dry leaf, for smoking. Canaccord estimates that by 2022, the THC-infused beverage market will still only be worth $340 million per annum, while the CBD-infused drinks market will only be worth $260 million. And, cannabis-infused beverages are also expected to make up only a fifth of the entire edibles market. ### Bottom Line for NBEV Stock Though competitors lie ahead in what will indeed likely be a modestly-sized market, New Age Beverages has the advantage of an established distribution channel, at least a little influence within the industry and a brand name linked to a prolific supporter of marijuana that helped reduce the stigma of its use. * 7 Stocks to Buy as the Dollar Weakens In that light, New Age Beverages may have just become one of the top names to beat within the niche. Though NBEV stock hasn't responded especially well to the news yet, time could still prove the full potential of the new product to skeptical investors. As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Growth Stocks With the Future Written All Over Them * 7 Reasons Why Buffett's Bet on Apple Stock Is a Good One * 10 Companies That Could Post Decelerating Profits Compare Brokers The post Cannabis-Infused Drinks Are a Slow Burn for NBEV Stock appeared first on InvestorPlace.
Analysts' January Rating Updates for TLRY, CGC, and ACB(Continued from Prior Part)TilrayTilray (TLRY), one of the top cannabis players in Canada, has been a favorite of day traders. The company has experienced wild swings, giving a hard time to
ACB, TLRY, and APHA Are in the Red, but CGC Continues to GainCannabis stocks are falling Aurora Cannabis (ACB) was trading in the red as of 11:00 AM EST today after the company announced that it would be raising $250 million worth of capital through
Analysts' January Rating Updates for TLRY, CGC, and ACBThree major stocks With a lot of action expected to boost the sentiments of cannabis investors (HMMJ), three major cannabis stocks are off to a positive start in 2019. These three stocks are
Clean Spark, Inc. (CLSK) has the best in class microgrid solution for the cannabis industry. Today we are highlighting: CleanSpark, Inc. (CLSK), Aurora Cannabis, Inc. (ACB), Tilray, Inc. (NASDAQ: TLRY), Charlotte's Web Holdings, Inc. (CWBHF), and KushCo Holdings, Inc. (KSHB).
At a time when rivals Tilray (NASDAQ:TLRY) and Aphria (NYSE:APHA) have captured headlines, Aurora Cannabis (NYSE:ACB) finally got a piece of the action again. Earlier this week, management announced its acquisition of premium-cannabis producer Whistler Medical Marijuana. As expected, ACB stock jumped on the news. More importantly for speculators, the enthusiasm hasn't faded yet, despite that we're now near the end of the week. A significant reason why Wall Street remains bullish is the acquisition's fundamental impact. For the most part, Aurora Cannabis stock is a direct play in medical marijuana. With Whistler, ACB has a broader portfolio. In addition, management must keep pace with key competitors. One of the biggest announcements in the sector was the partnership between Cronos Group (NASDAQ:CRON) and Altria Group (NYSE:MO). We all know about beverage-maker Constellation Brands' (NYSE:STZ) investment in Canopy Growth (NYSE:CGC). If you're not cutting deals in this sector, you're going nowhere. InvestorPlace - Stock Market News, Stock Advice & Trading Tips That's all fine and well. The most worrying factor here, however, is dilution in ACB stock. Including Whistler, Aurora has bought out nine companies. Ordinarily, such actions represent a strain on resources. The leadership team sidesteps the issue with all-stock purchases. * Top 10 Global Stock Ideas for 2019 From RBC Capital Last year, ACB acquired MedReleaf, Anandia Labs and ICC Labs. In total, the medical-cannabis firm spent $3.6 billion, all in equity. Because management refuses to tap into their cash reserves, Aurora Cannabis stock must take the hit, no pun intended. Currently, we have 994 million shares of ACB stock outstanding. Just two years ago, we had 313 million shares outstanding. By the time the Whistler deal and possible others are completed, we're looking at well over one billion shares. For those long Aurora, this dilutive strategy warrants concern. Still, it's too early to get pessimistic. ### With ACB Stock, Focus on the 'Why,' Not the 'How' Again, under ordinary circumstances, I'd sound the alarm on Aurora Cannabis stock. Diluting shares is a relatively easy way to expand your footprint. But get it wrong, and you could be courting disaster. Even without considering a worst-case scenario, dilutive strategies invite profitability and sustainability pressures. So what makes ACB stock different? It's all about the inherent nature of the legal-marijuana industry. Unlike almost every other market, cannabis has practically appeared out of nowhere. To deliver long-term success, companies must do everything they can to establish their brand. Therefore, traditional concerns like profitability take a backseat to growth and expansion. Logically, this strategy negatively impacts investments like ACB stock in the nearer-term. However, I'm afraid no other practical alternatives exist. Like crystal meth or hallucinogenic mushrooms, making weed is relatively easy. Thanks to platforms like YouTube, you can practice "pharmacy." But due to legalization, the black-market effect no longer bolsters marijuana prices. Therefore, cannabis firms must consolidate to survive as an industry. That's one reason why I'm not panicking over dilution in Aurora Cannabis stock. The other reason is differentiation. As I just mentioned, weed is easy to grow. What will separate the contenders from the pretenders is product quality. If you look at Whistler's product portfolio, you can see why management pulled the trigger. Contrary to prior eras, cannabis has dramatically evolved from just a means to get high. Today, medical-marijuana firms have "scienced" the snot out of the underlying commodity. In the foreseeable future, we'll enjoy a standardized industry where patients can match their symptoms with an ameliorating cannabis strain. To get there, ACB must lay down the foundations. That's why investors should focus on the "why" (in this case, future profitability), not the "how" (dilution). ### Be Carefully Optimistic Toward Aurora Cannabis Stock While I agree with management's overall direction, that doesn't guarantee a smooth ride. Analysts who raise the dilution concern aren't wrong. Every action has a reaction. At the very least, each share of ACB stock will be increasingly worth less. But I highly doubt that shares will become worthless. The deal-making and dilution represent the marijuana industry's harsh realities. Due to low barriers of entry on the production side, current cannabis firms must expand, partially to discourage competitors. And because traditional financiers are iffy about marijuana's Schedule I classification, for sector players, cash is king. Otherwise, going all-equity on every acquisition is unnecessarily risky. But again, that's just the reality. This investment category isn't for everyone because we know ahead of time that it's insanely and inevitably volatile. But a careful, longer-term approach to Aurora Cannabis stock should pay off quite nicely. As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Growth Stocks With the Future Written All Over Them * 7 Reasons Why Buffett's Bet on Apple Stock Is a Good One * 10 Companies That Could Post Decelerating Profits Compare Brokers The post You Can Trust Aurora Cannabis Stock Despite the Dilution appeared first on InvestorPlace.
It’s one of the world’s fastest growing plants—a separate species of the cannabis sativa genus that, due to its 0.3% tetrahydrocannabinol (THC) content, makes it literally almost impossible to get high from smoking it. Just weeks ago, U.S. President Trump signed the 2018 Farm Bill into law. The newly revamped bill legalizes industrial hemp in the U.S., and in doing so not only makes hemp and CBD eligible for lucrative federal crop insurance, but also removes CBD from the Controlled Substances Act.
Intrexon (XON) partners with Next Green Wave Holdings to utilize Intrexon's Botticelli next-generation plant propagation platform.
Ryan McQueeney covers the latest Brexit news and Snap's executive exodus. He also recaps earnings results from Goldman Sachs, Bank of America, and United Air Lines. Later, he discusses a busy week for deals in the cannabis industry.
CORAL GABLES, FL / ACCESSWIRE / January 16,2019 / Marijuana stocks have been anything but safe over the course of the past year to two years, during the course of which top players in the cannabis industry saw huge boosts in investor interest. With the new year in full swing, Leafbuyer Technologies Inc (LBUY), New Age Beverages Corp (NBEV), Canopy Growth Corp (CGC) (WEED.TO), and Tilray Inc (TLRY) are 4 pot stocks that could make moves on Wednesday. The Company has been referred to as the "Priceline of Pot" by several sources, and similarly to the site which provides travel deals, Leafbuyer is the most comprehensive online source for cannabis deals and specials.
Mid-Day Movers in the Cannabis Sector: CGC, TLRY, ACB, and MoreMid-day moversAround mid-day today, the major cannabis stocks were broadly positive. The Horizons Marijuana Life Sciences ETF (HMMJ) was up almost 1% around noon. Let’s look at how
These Cannabis Stocks Are Soaring in JanuaryCannabis stock trendsCannabis stock CannTrust Holdings (CNTTF) rose to $6.0 on January 15 from $4.8 at the close of market on December 31, 2018, representing a rise of ~25% in the first half of January